BAXTER INTL INC's ticker is BAX and the CUSIP is 071813109. A total of 952 filers reported holding BAXTER INTL INC in Q1 2017. The put-call ratio across all filers is 0.64 and the average weighting 0.3%.
About BAXTER INTL INC
Baxter International Inc. is a global healthcare company that specializes in developing and manufacturing medical products and therapies. The company has a long history of innovation and has been at the forefront of developing life-saving treatments for patients around the world.
Baxter's product portfolio includes a wide range of medical devices, pharmaceuticals, and biotechnology products. The company's products are used in hospitals, clinics, and other healthcare settings to treat a variety of conditions, including hemophilia, immune disorders, kidney disease, and other chronic and acute medical conditions.
Baxter's commitment to innovation has helped the company maintain a strong position in the healthcare industry. The company invests heavily in research and development, and has a strong pipeline of new products in development.
Baxter's leadership team is also a key strength of the company. The CEO, José Almeida, has a strong track record of success in the healthcare industry, and has been instrumental in driving the company's growth and success.
Overall, Baxter International Inc. is a strong and innovative company that is well-positioned to continue delivering value to patients, healthcare providers, and investors alike. With a strong product portfolio, a commitment to innovation, and a talented leadership team, Baxter is a company that investors should keep an eye on in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $371 | -99.9% | 7,286 | -28.6% | 0.06% | -71.0% |
| Q1 2017 | $529,000 | -4.5% | 10,208 | -18.3% | 0.21% | -24.2% |
| Q4 2016 | $554,000 | -7.8% | 12,500 | -1.0% | 0.28% | -30.8% |
| Q3 2016 | $601,000 | +5.4% | 12,629 | +0.2% | 0.40% | +0.8% |
| Q2 2016 | $570,000 | -28.1% | 12,601 | -34.7% | 0.40% | -51.3% |
| Q1 2016 | $793,000 | +5.0% | 19,307 | -2.5% | 0.82% | +10.4% |
| Q4 2015 | $755,000 | +12.9% | 19,794 | -2.8% | 0.74% | +11.8% |
| Q3 2015 | $669,000 | -53.1% | 20,373 | -0.1% | 0.66% | -49.5% |
| Q2 2015 | $1,427,000 | +4.8% | 20,403 | +2.6% | 1.31% | +3.2% |
| Q1 2015 | $1,362,000 | -99.9% | 19,889 | +14.9% | 1.27% | +22.3% |
| Q4 2014 | $1,268,577,000 | +101224.0% | 17,309 | +0.8% | 1.04% | -15.8% |
| Q3 2014 | $1,252,000 | -2.7% | 17,176 | -0.1% | 1.23% | -2.9% |
| Q2 2014 | $1,287,000 | +3.6% | 17,192 | -0.4% | 1.27% | +10.0% |
| Q1 2014 | $1,242,000 | +3.0% | 17,254 | -0.5% | 1.15% | +12.3% |
| Q4 2013 | $1,206,000 | – | 17,336 | – | 1.03% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 200,000 | $7,548,000 | 6.60% |
| BOONE CAPITAL MANAGEMENT LLC | 469,405 | $17,715,345 | 5.59% |
| Soditic Asset Management LLP | 186,920 | $7,054,361 | 5.43% |
| JONES ROAD CAPITAL MANAGEMENT, L.P. | 131,000 | $4,943,940 | 4.32% |
| Camber Capital Management LP | 3,000,000 | $113,220 | 3.73% |
| Carmignac Gestion | 4,848,773 | $182,991,718 | 3.36% |
| SHAPIRO CAPITAL MANAGEMENT LLC | 3,028,799 | $114,306,874 | 3.33% |
| Hillman Capital Management, Inc. | 219,248 | $8,274,420 | 3.19% |
| Cincinnati Specialty Underwriters Insurance CO | 201,500 | $7,604,610 | 2.90% |
| Callodine Capital Management, LP | 265,000 | $10,001,100 | 2.79% |